Thrombin-activatable fibrinolysis inhibitor

Jump to: navigation, search
carboxypeptidase B2
Identifiers
Symbol CPB2
Entrez 1361
HUGO 2300
OMIM 603101
RefSeq NM_001872
UniProt Q96IY4
Other data
Locus Chr. 13 q14.11

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Thrombin-activatable fibrinolysis inhibitor (TAFI), also known as plasma carboxypeptidase B2 is a recently described plasma zymogen that, when exposed to the thrombin-thrombomodulin complex, is converted by proteolysis at Arg92 to a basic carboxypeptidase (TAFIa or activated TAFI) that inhibits fibrinolysis.

TAFI is produced by the liver.

Fibrinolysis (simplified). Blue arrows denote stimulation, and red arrows inhibition.

WikiDoc Resources for Thrombin-activatable fibrinolysis inhibitor

Articles

Most recent articles on Thrombin-activatable fibrinolysis inhibitor

Most cited articles on Thrombin-activatable fibrinolysis inhibitor

Review articles on Thrombin-activatable fibrinolysis inhibitor

Articles on Thrombin-activatable fibrinolysis inhibitor in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Thrombin-activatable fibrinolysis inhibitor

Images of Thrombin-activatable fibrinolysis inhibitor

Photos of Thrombin-activatable fibrinolysis inhibitor

Podcasts & MP3s on Thrombin-activatable fibrinolysis inhibitor

Videos on Thrombin-activatable fibrinolysis inhibitor

Evidence Based Medicine

Cochrane Collaboration on Thrombin-activatable fibrinolysis inhibitor

Bandolier on Thrombin-activatable fibrinolysis inhibitor

TRIP on Thrombin-activatable fibrinolysis inhibitor

Clinical Trials

Ongoing Trials on Thrombin-activatable fibrinolysis inhibitor at Clinical Trials.gov

Trial results on Thrombin-activatable fibrinolysis inhibitor

Clinical Trials on Thrombin-activatable fibrinolysis inhibitor at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Thrombin-activatable fibrinolysis inhibitor

NICE Guidance on Thrombin-activatable fibrinolysis inhibitor

NHS PRODIGY Guidance

FDA on Thrombin-activatable fibrinolysis inhibitor

CDC on Thrombin-activatable fibrinolysis inhibitor

Books

Books on Thrombin-activatable fibrinolysis inhibitor

News

Thrombin-activatable fibrinolysis inhibitor in the news

Be alerted to news on Thrombin-activatable fibrinolysis inhibitor

News trends on Thrombin-activatable fibrinolysis inhibitor

Commentary

Blogs on Thrombin-activatable fibrinolysis inhibitor

Definitions

Definitions of Thrombin-activatable fibrinolysis inhibitor

Patient Resources / Community

Patient resources on Thrombin-activatable fibrinolysis inhibitor

Discussion groups on Thrombin-activatable fibrinolysis inhibitor

Patient Handouts on Thrombin-activatable fibrinolysis inhibitor

Directions to Hospitals Treating Thrombin-activatable fibrinolysis inhibitor

Risk calculators and risk factors for Thrombin-activatable fibrinolysis inhibitor

Healthcare Provider Resources

Symptoms of Thrombin-activatable fibrinolysis inhibitor

Causes & Risk Factors for Thrombin-activatable fibrinolysis inhibitor

Diagnostic studies for Thrombin-activatable fibrinolysis inhibitor

Treatment of Thrombin-activatable fibrinolysis inhibitor

Continuing Medical Education (CME)

CME Programs on Thrombin-activatable fibrinolysis inhibitor

International

Thrombin-activatable fibrinolysis inhibitor en Espanol

Thrombin-activatable fibrinolysis inhibitor en Francais

Business

Thrombin-activatable fibrinolysis inhibitor in the Marketplace

Patents on Thrombin-activatable fibrinolysis inhibitor

Experimental / Informatics

List of terms related to Thrombin-activatable fibrinolysis inhibitor



Linked-in.jpg